scholarly journals Parvovirus B19-induced Pure Red Cell Aplasia in a Liver Transplant Recipient

2010 ◽  
Vol 30 (6) ◽  
pp. 591-594 ◽  
Author(s):  
Eun Young Lee ◽  
Yonggeun Cho ◽  
Sang-Guk Lee ◽  
Jaewoo Song
2012 ◽  
Vol 52 (186) ◽  
Author(s):  
A Baral ◽  
B Poudel ◽  
R K Agrawal ◽  
R Hada ◽  
S Gurung

Parvo B19 is a single stranded DNA virus, which typically has affi nity for erythroid progenitor cells in the bone marrow and produces a severe form of anemia known as pure red cell aplasia. This condition is particularly worse in immunocompromised individuals. We herein report a young Nepali male who developed severe and persistent anaemia after kidney transplantation while being on immunosuppressive therapy. His bone marrow examination revealed morphological changes of pure red cell aplasia, caused by parvovirus B19. The IgM antibody against the virus was positive and the virus was detected by polymerase chain reaction in the blood. He was managed with intravenous immunoglobulin. He responded well to the treatment and has normal hemoglobin levels three months post treatment. To the best of our knowledge, this is the fi rst such case report from Nepal. Keywords: Intravenous immunoglobulin, kidney transplant recipient, Parvovirus B19, pure red cell aplasia.


2009 ◽  
Vol 54 (1) ◽  
pp. 68-69 ◽  
Author(s):  
Naoki Uemura ◽  
Keiya Ozawa ◽  
Kenzaburo Tani ◽  
Mitsuo Nishikawa ◽  
Sumio Inoue ◽  
...  

2016 ◽  
Vol 4 (9) ◽  
pp. 870-871 ◽  
Author(s):  
Rosangela Invernizzi ◽  
Raffaella Bastia ◽  
Federica Quaglia

Blood ◽  
2000 ◽  
Vol 96 (3) ◽  
pp. 1184-1186 ◽  
Author(s):  
Vivek R. Sharma ◽  
Donald R. Fleming ◽  
Stephen P. Slone

Abstract Rituximab is a chimeric monoclonal antibody directed against CD20 and used in the treatment of B-cell non-Hodgkin's lymphoma. Due to its ability to deplete B lymphocytes, rituximab can interfere with humoral immunity, causing it to be suppressed for several months after treatment. The reported case depicts a serious consequence of this effect of rituximab therapy: pure red cell aplasia resulting from chronic parvovirus B19 infection. The point of interest in this case is not only the association between rituximab therapy and pure red cell aplasia, but the diagnostic and therapeutic utility of the knowledge of parvovirus B19 as the likely etiologic link between the two. Given the known efficacy of intravenous immunoglobulin (IVIg) in the treatment of chronic parvovirus B19 infection, this therapy can cure some of these patients and successfully render most others transfusion-independent until recovery of their own humoral immune system.


2017 ◽  
Vol 2 (2) ◽  
pp. S19-S20
Author(s):  
Putun Patel ◽  
Vibha Bafna ◽  
Sandip Bartakke ◽  
Priya Gupta ◽  
Sanjay Mankar ◽  
...  

2020 ◽  
Vol 52 (8) ◽  
pp. 2539-2543 ◽  
Author(s):  
Ewa Nowacka-Cieciura ◽  
Ewa Karakulska-Prystupiuk ◽  
Anna Żuk-Wasek ◽  
Wojciech Lisik ◽  
Grzegorz Władysław Basak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document